Clinical validity and intrarater and test–retest reliability of the Structured Clinical Interview for DSM‐5 – Clinician Version (SCID‐5‐CV)
Flávia de Lima Osório(Universidade de Ribeirão Preto), José Alexandre S. Crippa(Universidade de São Paulo), Rocío Martín‐Santos(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Ana Paula Casagrande Silva‐Rodrigues(Clinics Hospital of Ribeirão Preto), Thiago D. Apolinario(Clinics Hospital of Ribeirão Preto), Fernanda Aguiar Pizeta, Victor S. Fracon(Clinics Hospital of Ribeirão Preto), Rafael G. dos Santos(Universidade de Ribeirão Preto), João Paulo Machado‐de‐Sousa(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Lívia Maria Bolsoni, Juliana Mayumi Ushirohira(Clinics Hospital of Ribeirão Preto), Sônia Regina Loureiro(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Cristiane von Werne Baes(Clinics Hospital of Ribeirão Preto), Jaime E. C. Hallak(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Roberto Mascarenhas Souza, Rafael Faria Sanches(Universidade de Ribeirão Preto), Thiago M. Guimarães, Mariana Fortunata Donadon
Cited by 338
Related Papers
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
|Psychological Medicine|2018|819
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
|Neuropsychopharmacology|2011|763
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
|Journal of Psychopharmacology|2010|530
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
|Brazilian Journal of Psychiatry|2015|484
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression
|Journal of Clinical Psychopharmacology|2015|465